Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Jahr

2021

Autoren

Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fernández Ó, Havrdová EK, Nakamura K, Traboulsee A, Ziemssen T, Jacobs A, Margolin DH, Huang X, Daizadeh N, Chirieac MC, Selmaj KW.

Verlag

Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134.

Link

https://doi.org/10.1177/1756286420982134

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

Consensus quality indicators for monitoring multiple sclerosis

Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany

Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab